View of An Open-Label Study Evaluating the Long-Term Efficacy, Quality of Life, and Safety of Lidose-Isotretinoin (ABSORICA) Capsules Administered Without Food in Patients with Severe Recalcitrant Nodular Acne: Interim Analysis of 20-Week Active Treatment Period

Return to Article Details An Open-Label Study Evaluating the Long-Term Efficacy, Quality of Life, and Safety of Lidose-Isotretinoin (ABSORICA) Capsules Administered Without Food in Patients with Severe Recalcitrant Nodular Acne: Interim Analysis of 20-Week Active Treatment Period Download Download PDF